F M Investments LLC Acquires New Stake in Savara Inc (NASDAQ:SVRA)

F M Investments LLC bought a new stake in shares of Savara Inc (NASDAQ:SVRA) in the fourth quarter, Holdings Channel reports. The firm bought 81,343 shares of the company’s stock, valued at approximately $250,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after buying an additional 365,959 shares in the last quarter. State Street Corp increased its holdings in Savara by 15.7% during the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after purchasing an additional 560,242 shares during the period. Geode Capital Management LLC raised its position in Savara by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock valued at $8,549,000 after purchasing an additional 57,187 shares in the last quarter. Rosalind Advisors Inc. purchased a new position in shares of Savara in the 4th quarter valued at about $8,151,000. Finally, Emerald Advisers LLC acquired a new position in shares of Savara during the fourth quarter worth about $7,161,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

NASDAQ:SVRA opened at $2.92 on Friday. The firm has a market cap of $504.09 million, a price-to-earnings ratio of -6.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.33. The firm’s fifty day moving average price is $2.72 and its 200 day moving average price is $3.13.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. On average, sell-side analysts expect that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Savara in a research note on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.